Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study

Authors: Shadman, Mazyar ^*, Flinn, Ian W, Levy, Moshe Y, Porter, Ryan F, Burke, John M, Zafar, Syed F, Misleh, Jamal, Kingsley, Edwin C, Yimer, Habte A, Freeman, Benjamin, Rao, Subramanya S, Chaudhry, Arvind, Tumula, Praveen K, Gandhi, Mitul D, Manda, Sudhir, Chen, Dih-Yih, By, Kunthel, Xu, Linlin, Liu, Ye, Crescenzo, Rocco, Idoine, Adam, Zhang, Xiaoping, Cohen, Aileen, Huang, Jane, Sharman, Jeff P

Source: In The Lancet Haematology January 2023 10(1):e35-e45

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Authors: Shadman, Mazyar, Flinn, Ian W., Levy, Moshe Y., Porter, Ryan, Burke, John M., Cultrera, Jennifer L., Misleh, Jamal, Zafar, Syed F., Freeman, Benjamin, Rao, Subramanya S., Yimer, Habte, Chaudhry, Arvind, Gandhi, Mitul D., Guthrie, Troy H., Kingsley, Edwin, Tumula, Praveen K., Manda, Sudhir, Chen, Dih-Yih, Cohen, Aileen, By, Kunthel, Xu, Linlin, Liu, Ye, Sharman, Jeff P.

Source: In Blood 23 November 2021 138 Supplement 1:1410-1410